-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Vanda Pharmaceuticals, Raises Price Target to $14

Benzinga·12/31/2025 17:33:31
語音播報
B. Riley Securities analyst Madison El-Saadi maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and raises the price target from $11 to $14.